EvenBetter99
$CLRB revolutionary Phospholipid Drug Conjugate (PDC) technology provides high-precision oncology delivery by directly targeting cancer cell membranes while sparing healthy tissue. Fir example WaM efficency over 83.6% ORR, 61.8 % MRR, 100 % CBR💪💪💪
This highly versatile platform forms the basis for their crucial Phase 1b catalyst trial evaluating the Auger-emitting radioconjugate CLR 125. It brings remarkable new hope as a highly effective, tailored treatment for patients fighting refractory triple-negative breast cancer (TNBC) and validates the plattform immensly. 🍀🍀🍀🍀🚀🚀🚀
3
